Nektar Therapeutics

Healthcare · Biotechnology

43.60$ -7.3% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Nektar Therapeutics (NKTR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 280 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NKTR
Line item	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	42	120	134	227	630	667	607	617	745	859	768	725	561	576	521	607	498	435	442	502	569	509	2,150	1,977	1,539	1,117	711	398	304	280
Current Assets	38	101	85	147	493	361	311	306	455	520	535	523	406	414	354	277	315	258	288	350	426	327	1,438	1,422	1,138	796	546	331	261	266
Cash	19	15	25	33	136	31	35	64	104	261	64	76	156	50	18	15	25	39	12	56	60	4.8	195	96	199	25	88	35	44	15
Cash & Short-Term Investments	19	100	83	138	485	344	294	286	419	476	459	482	379	396	316	241	277	237	238	309	389	296	1,335	1,325	1,062	734	505	304	255	246
Receivables	–	–	–	1.8	7.2	4.5	4.4	6.2	13	8.2	47	22	11	4.8	25	4.9	5.8	2.2	3.6	20	16	5.0	43	37	39	22	8.4	2.3	1.6	1.8
Inventory	–	–	–	–	–	3.2	6.3	8.6	11	19	15	12	9.3	6.5	7.3	13	18	13	13	11	11	11	11	13	15	16	19	16	0.0	–
Property, Plant & Equipment	–	–	–	–	110	142	143	149	151	142	134	114	74	78	90	79	72	67	70	71	66	47	49	65	60	178	86	–	–	–
Goodwill	–	–	–	–	–	132	130	130	130	78	78	78	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	0.0	–	–
Intangible Assets	–	–	–	–	–	154	146	141	137	13	3.6	2.7	77	77	77	77	77	77	77	77	77	77	–	27	–	–	–	–	–	–
Total Liabilities	6.4	23	19	140	352	397	400	453	278	532	541	511	370	473	431	409	451	524	405	496	481	421	433	572	461	438	344	267	243	191
Current Liabilities	6.2	17	13	25	30	59	64	47	56	70	165	98	68	153	64	276	79	98	64	61	72	56	82	354	116	85	68	51	61	54
Short-Term Debt	0.2	0.1	0.1	0.0	1.0	0.8	1.0	1.6	1.5	0.5	103	2.3	39	29	30	217	41	44	4.5	9.5	5.8	32	62	265	14	17	19	19	20	20
Accounts Payable	1.1	6.0	3.7	13	6.5	7.7	8.7	8.1	7.1	19	8.2	3.6	14	3.1	7.2	3.0	2.9	9.1	2.7	2.4	2.8	4.8	5.9	19	22	9.7	13	9.8	12	11
Long-Term Debt	–	–	–	–	319	331	331	392	208	439	335	337	235	234	232	15	125	125	125	242	243	245	247	–	–	–	–	–	–	–
Shareholders' Equity	35	97	116	87	278	270	207	164	467	327	227	214	190	102	91	198	47	-90	36	6.4	88	88	1,718	1,405	1,077	680	367	131	61	90
Retained Earnings	-28	-38	-56	-94	-192	-442	-549	-596	-717	-902	-1,057	-1,090	-1,124	-1,227	-1,265	-1,399	-1,570	-1,732	-1,786	-1,867	-2,021	-2,118	-1,424	-1,865	-2,309	-2,833	-3,201	-3,477	-3,596	-3,760
Shares Outstanding	1.5	1.8	2.1	2.3	2.8	3.5	3.7	3.7	5.2	5.7	6.0	6.1	6.2	6.2	6.3	7.5	7.7	7.7	8.5	8.8	9.3	10	12	12	12	12	12	13	14	17

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings